Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05860348 · ClinicalTrials.gov registry record
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
A clinical trial, sponsored by CVRx.
- Terminated
- Registry status
- 5
- Enrollment target
NCT05860348: Clinical Trial study, sponsored by CVRx.
NCT05860348 is a clinical trial that was terminated before completion, run by CVRx. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05860348 was terminated before completion, sponsored by CVRx.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
Primary Outcome
Changes in Six Minute Hall Walk distance through 36 months post-implant
Interventions
- DEVICE Barostim™ System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2024-12-11 |
Why NCT05860348 stopped before completion
NCT05860348 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Barostim™ System is the first listed.
NCT05860348 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05860348 about?
NCT05860348 is a clinical study titled "Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence". The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
What is the current status of trial NCT05860348?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2023-07-25. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT05860348?
The interventions under investigation include: Barostim™ System (DEVICE).
Who is sponsoring clinical trial NCT05860348?
This trial is sponsored by CVRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI